Sylvie Ponchaut, Managing Director Biowin, commented:“BioWin is proud to enrich its portfolio with BidMed, this collaborative and innovative program gathering leaders in the field of proton therapy and digital technologies. By joining our forces in improving personalized cancer treatment, these actors are responding to an important need of the patient and contribute to the reinforcement of the excellence of Wallonia.”
About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.
About Telemis
Telemis specialises in the development of medical imaging software and more specifically PACS (Picture Archiving and Communication System) software. The Telemis product line aims to assist hospitals, clinics and private practices to manage digital medical images and to eliminate the need for X-ray film, thereby reducing costs and increasing the quality of the care provided.
Created in 1999 as a start-up from advanced university research, Telemis is located on the campus of the Université Catholique de Louvain (UCL) in Louvain-La-Neuve, Belgium with international offices in Luxembourg, Paris, Toulouse, Turin, and Neuchâtel. It shares and collaborates with UCL and other top-notch university centers on technology development and, as a leading provider of integrated medical imaging IT solutions, 244 hospitals, and other healthcare centres use its products across Europe, Middle East, and Africa.
Back to HCB News
